Date:1/25/2010

as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K and in Thoratec's second quarter 2009 quarterly report on Form 10-Q, and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

SOURCE Thoratec Corporation

RELATED LINKS
http://www.thoratec.com
http://www.itcmed.com

'/>"/>

SOURCE Thoratec Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
2. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
3. Thoratec Presentation at Piper Jaffray Conference to be Webcast
4. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
5. Thoratec Presentation at Canaccord Adams Conference to be Webcast
6. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
7. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
8. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
9. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
10. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
11. Warner Chilcott Announces 2010 Financial Guidance Conference Call